Kaposi’s Sarcoma in Virally Suppressed People Living with HIV: An Emerging Condition

Since the advent of highly effective combined antiretroviral treatment (cART), and with the implementation of large HIV testing programs and universal access to cART, the burden of AIDS-related comorbidities has dramatically decreased over time. The incidence of Kaposi’s sarcoma (SK), strongly assoc...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Romain Palich, Alain Makinson, Marianne Veyri, Amélie Guihot, Marc-Antoine Valantin, Sylvie Brégigeon-Ronot, Isabelle Poizot-Martin, Caroline Solas, Sophie Grabar, Guillaume Martin-Blondel, Jean-Philippe Spano
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	Kaposi’s sarcoma HIV AIDS antiretroviral cancer Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/da621ce9e57f44e5baeff44267545a42
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:da621ce9e57f44e5baeff44267545a42
record_format	dspace
spelling	oai:doaj.org-article:da621ce9e57f44e5baeff44267545a422021-11-25T17:02:51ZKaposi’s Sarcoma in Virally Suppressed People Living with HIV: An Emerging Condition10.3390/cancers132257022072-6694https://doaj.org/article/da621ce9e57f44e5baeff44267545a422021-11-01T00:00:00Zhttps://www.mdpi.com/2072-6694/13/22/5702https://doaj.org/toc/2072-6694Since the advent of highly effective combined antiretroviral treatment (cART), and with the implementation of large HIV testing programs and universal access to cART, the burden of AIDS-related comorbidities has dramatically decreased over time. The incidence of Kaposi’s sarcoma (SK), strongly associated with HIV replication and CD4 immunosuppression, was greatly reduced. However, KS remains the most common cancer in patients living with HIV (PLHIV). HIV physicians are increasingly faced with KS in virally suppressed HIV-patients, as reflected by increasing description of case series. Though SK seem less aggressive than those in PLHIV with uncontrolled HIV-disease, some may require systemic chemotherapy. Persistent lack of specific anti-HHV-8 cellular immunity could be involved in the physiopathology of these KS. These clinical forms are a real therapeutic challenge without possible short-term improvement of anti-HHV-8 immunity, and no active replication of HIV to control. The cumulative toxicity of chemotherapies repeatedly leads to a therapeutic dead end. The introduction or maintenance of protease inhibitors in cART does not seem to have an impact on the evolution of these KS. Research programs in this emerging condition are important to consider new strategies.Romain PalichAlain MakinsonMarianne VeyriAmélie GuihotMarc-Antoine ValantinSylvie Brégigeon-RonotIsabelle Poizot-MartinCaroline SolasSophie GrabarGuillaume Martin-BlondelJean-Philippe SpanoMDPI AGarticleKaposi’s sarcomaHIVAIDSantiretroviralcancerNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENCancers, Vol 13, Iss 5702, p 5702 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Kaposi’s sarcoma HIV AIDS antiretroviral cancer Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	Kaposi’s sarcoma HIV AIDS antiretroviral cancer Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Romain Palich Alain Makinson Marianne Veyri Amélie Guihot Marc-Antoine Valantin Sylvie Brégigeon-Ronot Isabelle Poizot-Martin Caroline Solas Sophie Grabar Guillaume Martin-Blondel Jean-Philippe Spano Kaposi’s Sarcoma in Virally Suppressed People Living with HIV: An Emerging Condition
description	Since the advent of highly effective combined antiretroviral treatment (cART), and with the implementation of large HIV testing programs and universal access to cART, the burden of AIDS-related comorbidities has dramatically decreased over time. The incidence of Kaposi’s sarcoma (SK), strongly associated with HIV replication and CD4 immunosuppression, was greatly reduced. However, KS remains the most common cancer in patients living with HIV (PLHIV). HIV physicians are increasingly faced with KS in virally suppressed HIV-patients, as reflected by increasing description of case series. Though SK seem less aggressive than those in PLHIV with uncontrolled HIV-disease, some may require systemic chemotherapy. Persistent lack of specific anti-HHV-8 cellular immunity could be involved in the physiopathology of these KS. These clinical forms are a real therapeutic challenge without possible short-term improvement of anti-HHV-8 immunity, and no active replication of HIV to control. The cumulative toxicity of chemotherapies repeatedly leads to a therapeutic dead end. The introduction or maintenance of protease inhibitors in cART does not seem to have an impact on the evolution of these KS. Research programs in this emerging condition are important to consider new strategies.
format	article
author	Romain Palich Alain Makinson Marianne Veyri Amélie Guihot Marc-Antoine Valantin Sylvie Brégigeon-Ronot Isabelle Poizot-Martin Caroline Solas Sophie Grabar Guillaume Martin-Blondel Jean-Philippe Spano
author_facet	Romain Palich Alain Makinson Marianne Veyri Amélie Guihot Marc-Antoine Valantin Sylvie Brégigeon-Ronot Isabelle Poizot-Martin Caroline Solas Sophie Grabar Guillaume Martin-Blondel Jean-Philippe Spano
author_sort	Romain Palich
title	Kaposi’s Sarcoma in Virally Suppressed People Living with HIV: An Emerging Condition
title_short	Kaposi’s Sarcoma in Virally Suppressed People Living with HIV: An Emerging Condition
title_full	Kaposi’s Sarcoma in Virally Suppressed People Living with HIV: An Emerging Condition
title_fullStr	Kaposi’s Sarcoma in Virally Suppressed People Living with HIV: An Emerging Condition
title_full_unstemmed	Kaposi’s Sarcoma in Virally Suppressed People Living with HIV: An Emerging Condition
title_sort	kaposi’s sarcoma in virally suppressed people living with hiv: an emerging condition
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/da621ce9e57f44e5baeff44267545a42
work_keys_str_mv	AT romainpalich kaposissarcomainvirallysuppressedpeoplelivingwithhivanemergingcondition AT alainmakinson kaposissarcomainvirallysuppressedpeoplelivingwithhivanemergingcondition AT marianneveyri kaposissarcomainvirallysuppressedpeoplelivingwithhivanemergingcondition AT amelieguihot kaposissarcomainvirallysuppressedpeoplelivingwithhivanemergingcondition AT marcantoinevalantin kaposissarcomainvirallysuppressedpeoplelivingwithhivanemergingcondition AT sylviebregigeonronot kaposissarcomainvirallysuppressedpeoplelivingwithhivanemergingcondition AT isabellepoizotmartin kaposissarcomainvirallysuppressedpeoplelivingwithhivanemergingcondition AT carolinesolas kaposissarcomainvirallysuppressedpeoplelivingwithhivanemergingcondition AT sophiegrabar kaposissarcomainvirallysuppressedpeoplelivingwithhivanemergingcondition AT guillaumemartinblondel kaposissarcomainvirallysuppressedpeoplelivingwithhivanemergingcondition AT jeanphilippespano kaposissarcomainvirallysuppressedpeoplelivingwithhivanemergingcondition
_version_	1718412807790133248

Kaposi’s Sarcoma in Virally Suppressed People Living with HIV: An Emerging Condition

Ejemplares similares